Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice.

Molecular events preceding the development of hepatocellular carcinoma were studied in the Mdr2-knockout (Mdr2-KO) mice. These mice lack the liver-specific P-glycoprotein responsible for phosphatidylcholine transport across the canalicular membrane. Portal inflammation ensues at an early age followed by hepatocellular carcinoma development after the age of 1 year. Liver tissue samples of Mdr2-KO mice in the early and late precancerous stages of liver disease were subjected to histologic, biochemical, and gene expression profiling analysis. In an early stage, multiple protective mechanisms were found, including induction of many anti-inflammatory and antioxidant genes and increase of total antioxidant capacity of liver tissue. Despite stimulation of hepatocyte DNA replication, their mitotic activity was blocked at this stage. In the late stage of the disease, although the total antioxidant capacity of liver tissue of Mdr2-KO mice was normal, and inflammation was less prominent, many protective genes remained overexpressed. Increased mitotic activity of hepatocytes resulted in multiple dysplastic nodules, some of them being steatotic. Expression of many genes regulating lipid and phospholipid metabolism was distorted, including up-regulation of choline kinase A, a known oncogene. Many other oncogenes, including cyclin D1, Jun, and some Ras homologues, were up-regulated in Mdr2-KO mice at both stages of liver disease. However, we found no increase of Ras activation. Our data suggest that some of the adaptive mechanisms induced in the early stages of hepatic disease, which protect the liver from injury, could have an effect in hepatocarcinogenesis at later stages of the disease in this hepatocellular carcinoma model.

[1]  K. Zatloukal,et al.  [116] TAURINE-CONJUGATION CRITICALLY DETERMINES THE THERAPEUTIC EFFECTIVENESS OF 24-NOR-URSODEOXYCHOLIC ACID (NORUDCA) IN THE TREATMENT OF SCLEROSING CHOLANGITIS IN MDR2 (ABCB4) KNOCKOUT MICE , 2007 .

[2]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[3]  C. Jobin,et al.  Serum amyloid A activates NF‐κB and proinflammatory gene expression in human and murine intestinal epithelial cells , 2005, European journal of immunology.

[4]  J. Scher,et al.  15d-PGJ2: the anti-inflammatory prostaglandin? , 2005, Clinical immunology.

[5]  Michael A. Gonzalez,et al.  Cell‐cycle‐dependent regulation of DNA replication and its relevance to cancer pathology , 2005, The Journal of pathology.

[6]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[7]  N. Devoogdt,et al.  Secretory Leukocyte Protease Inhibitor in Cancer Development , 2004, Annals of the New York Academy of Sciences.

[8]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[9]  J. Bocco,et al.  A new role for the Krüppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function , 2004, Oncogene.

[10]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[11]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[12]  Y. Kloog,et al.  Galectin-3 Augments K-Ras Activation and Triggers a Ras Signal That Attenuates ERK but Not Phosphoinositide 3-Kinase Activity* , 2004, Journal of Biological Chemistry.

[13]  H. Tilg,et al.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.

[14]  S. Friedman,et al.  Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1 , 2004, Cancer Research.

[15]  N. McElvaney,et al.  Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells , 2004, Infection and Immunity.

[16]  I. Cho,et al.  Transactivation of the PPAR-Responsive Enhancer Module in Chemopreventive Glutathione S-Transferase Gene by the Peroxisome Proliferator-Activated Receptor-γ and Retinoid X Receptor Heterodimer , 2004, Cancer Research.

[17]  D. A. Foster,et al.  The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  G. Souza,et al.  Serum amyloid A-induced mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human neutrophils. , 2004, Immunology letters.

[19]  J. Klaunig,et al.  The role of oxidative stress in carcinogenesis. , 2004, Annual review of pharmacology and toxicology.

[20]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[21]  S. Safe,et al.  Peroxisome Proliferator-activated Receptor γ Agonists Induce Proteasome-dependent Degradation of Cyclin D1 and Estrogen Receptor α in MCF-7 Breast Cancer Cells , 2003 .

[22]  B. Brewer,et al.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.

[23]  Qingxian Lu,et al.  Macrophage regulation by Tyro 3 family receptors. , 2003, Current opinion in immunology.

[24]  E. Wagner,et al.  Liver Tumor Development c-Jun Antagonizes the Proapoptotic Activity of p53 , 2003, Cell.

[25]  F. Gonzalez,et al.  Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-activated Receptor γ1 (PPARγ1) Overexpression* , 2003, The Journal of Biological Chemistry.

[26]  J. Reddy,et al.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. , 2003, The Journal of biological chemistry.

[27]  M. Oren,et al.  Nuclear factor-kappaB protects the liver against genotoxic stress and functions independently of p53. , 2003, Cancer research.

[28]  R. Eckel,et al.  Lipoprotein lipase : genetics , lipid uptake , and regulation , 2002 .

[29]  J. Auwerx,et al.  Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases , 2002, The Lancet.

[30]  Y. Kloog,et al.  Galectin-1 Augments Ras Activation and Diverts Ras Signals to Raf-1 at the Expense of Phosphoinositide 3-Kinase* , 2002, The Journal of Biological Chemistry.

[31]  M. Aviram,et al.  Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. , 2002, Atherosclerosis.

[32]  Y. Shyr,et al.  Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. , 2001, Cancer research.

[33]  S. Hirono,et al.  Transduction of antisense cyclin D1 using two-step gene transfer inhibits the growth of rat hepatoma cells. , 2001, Cancer research.

[34]  Y. Nishizuka The protein kinase C family and lipid mediators for transmembrane signaling and cell regulation. , 2001, Alcoholism, clinical and experimental research.

[35]  P. Kuo,et al.  Osteopontin Is a Negative Feedback Regulator of Nitric Oxide Synthesis in Murine Macrophages1 , 2001, The Journal of Immunology.

[36]  M. Sakaguchi,et al.  Relationship between Contact Inhibition and Intranuclear S100c of Normal Human Fibroblasts , 2000, The Journal of cell biology.

[37]  G. Getz,et al.  Coupled two-way clustering analysis of gene microarray data. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Kawagoe,et al.  Attenuation of luminol-amplified chemiluminescent intensity and lipid peroxidation in the livers of quercetin-fed mice. , 2000, Toxicology letters.

[39]  O. Tirosh,et al.  Quantification of the overall reactive oxygen species scavenging capacity of biological fluids and tissues. , 2000, Free radical biology & medicine.

[40]  S. Thorgeirsson,et al.  Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[42]  Blatt,et al.  Superparamagnetic clustering of data. , 1998, Physical review letters.

[43]  I. Weinstein Relevance of cyclin D1 and other molecular markers to cancer chemoprevention , 1996, Journal of cellular biochemistry. Supplement.

[44]  P. Laipis,et al.  Multiple Deletions Are Detectable in Mitochondrial DNA of Aging Mice (*) , 1995, The Journal of Biological Chemistry.

[45]  S. Zeisel,et al.  Choline and hepatocarcinogenesis in the rat. , 1995, Advances in experimental medicine and biology.

[46]  A. Groen,et al.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.

[47]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[48]  G. Cooper,et al.  Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction , 1993, Molecular and cellular biology.

[49]  P. Borst,et al.  Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.

[50]  L. Ellwein,et al.  Genetic errors, cell proliferation, and carcinogenesis. , 1991, Cancer research.

[51]  E. Farber,et al.  The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. , 1984, Carcinogenesis.